Month: September 2025

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 1,034,433 shares of its common stock at an offering price of $67.67 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 960,542 shares of common stock at the purchase price of $67.669 per pre-funded warrant, which represents the offering price per share for the common stock less a $0.001 per share exercise price. The gross proceeds to Monopar from the offering net of the anticipated Stock Repurchase (as defined below), but before deducting the underwriting...

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the Journal of Hepatology has published a peer-reviewed Letter to the Editor (link), authored by leading Wilson disease physicians, entitled “Oral Bis-choline Tetrathiomolybdate Rapidly Improves Copper Balance in Patients with Wilson Disease.” Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in organs such as the liver and brain. In the Letter to the Editor, the authors explain that the earlier conclusion from the Phase 2 ALXN1840-WD-204 study (NCT04573309)...

VANCOUVER, British Columbia, Sept. 23, 2025 (GLOBE NEWSWIRE) — Zacatecas Silver Corp. (TSXV: ZAC; OTC: ZCTSF) (the “Company”) is pleased to announce that it has closed the first tranche of its previously announced private placement financing by issuing a total of 38,449,335 units (“Units”) at a price of $0.06 per Unit for gross proceeds of $2,306,960. The Company anticipates it will complete the final tranche by September 29, 2025. Each Unit consists of one common share (a “Share”) and one common share purchase warrant (a “Warrant”), with each Warrant exercisable at $0.10 per Share for a period of two years from the date of issue (the “Expiry Date”). The Company has the right to accelerate the Expiry Date if, at any time, the volume weighted average price of the Shares on the principal exchange or market on which the Shares trade...

WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) — Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the “Irish Takeover Rules”), that it has published the definitive proxy statement of Mural relating to the Acquisition described below, which also constitutes a scheme circular under Irish law (the “Proxy Statement”) and that Mural has commenced mailing the Proxy Statement to Mural shareholders. As previously announced on August 20, 2025, XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”) and Mural entered into a definitive transaction agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty (“Sub”), has agreed to acquire the entire issued...

MONTREAL, Sept. 23, 2025 (GLOBE NEWSWIRE) — Gildan Activewear Inc. (GIL: TSX and NYSE) (“Gildan” or the “Company”) announced today that it has priced an offering of US$1.2 billion aggregate principal amount of senior unsecured notes in two series, consisting of US$600 million aggregate principal amount of 4.700% senior unsecured notes, due October 7, 2030 and US$600 million aggregate principal amount of 5.400% senior unsecured notes, due October 7, 2035 (together, the “Notes”). The Company expects to use the net proceeds from the offering of the Notes, together with cash on hand or other immediately available funds, to fund the cash portion of the consideration to be paid for the acquisition of Hanesbrands Inc., the refinancing of Hanesbrands’ existing indebtedness and related transaction fees and expenses related to the offering...

CALGARY, Alberta, Sept. 23, 2025 (GLOBE NEWSWIRE) — FLINT Corp. (“FLINT” or the “Company“) (TSX: FLNT) is pleased to announce the completion of its recapitalization transaction (the “Recapitalization“), as described in the Company’s management information circular dated August 20, 2025. The Recapitalization was implemented pursuant to a court-approved plan of arrangement (“Plan of Arrangement“) under the Business Corporations Act (Alberta) (the “ABCA“). Pursuant to the Recapitalization, the common shares in the capital of the Company (the “Common Shares“) were consolidated (the “Consolidation“) at a ratio of one post-consolidation Common Share for every 40 pre-consolidation Common Shares. Immediately following the Consolidation, (i) all of...

TORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) — Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) today comments on ongoing social unrest in Peru. After a period of heightened social pressures over the past few months, the situation has escalated over the weekend with riots in Lima and several protests across the country. Along with other mines in the southern mining corridor, Hudbay’s Constancia mine has been impacted by local protests and illegal blockades. The safety of all personnel is the Company’s top priority, and Hudbay has taken precautions intended to ensure their safety, including a temporary demobilization of the non-essential workforce. While the Constancia mill continued to operate over the weekend, in light of the recent demonstrations near Constancia, the mill has been temporarily shut down as a safety...

TORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) — Avidian Gold Corp. (“Avidian” or the “Corporation”) (TSX-V: AVG) today announces that it has closed the first tranche of a share purchase agreement dated September 16, 2025 (the “Agreement”) with an arm’s length purchaser pursuant to which it sold 4,700,000 common shares (the “First Tranche Shares”) of High Tide Resources Corp. (“High Tide”) at a price of $0.04 per First Tranche Share (the “Sale Price”). Pursuant to the Agreement, the Corporation has agreed to sell an additional 2,300,000 common shares of High Tide (the “Second Tranche Shares”, and together with the First Tranche Shares, the “Subject Shares”, and the common shares in the capital of High Tide, the “High Tide Shares”) at the Sale Price. The issuance of the Second Tranche Shares is expected to close on or around October 8,...

CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on September 22, 2025, the Lifecore compensation committee approved the grant under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of a restricted stock unit (“RSU”) award with respect to 15,000 shares of its common stock and stock options for 30,000 shares of common stock to a newly hired employee of Lifecore. The RSU award and stock options were granted on September 22, 2025, pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award and stock options were approved by Lifecore’s compensation committee and were granted as...